Pure Global
NCT06236841

A Phase I Study of XH-S004 in Healthy Volunteers

A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Food Effects of XH-S004 Single and Multiple Ascending Doses in Healthy Volunteers
S-Infinity Pharmaceuticals Co., Ltd·Phase 1·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Healthy Adults
Drug/Device/Intervention
XH-S004 tablet
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
S-Infinity Pharmaceuticals Co., Ltd
Location
Beijing, China
Timeline & enrollment
Phase
Phase 1
Start date
Jan 26, 2024
End date
Jan 31, 2025
Enrollment
90 participants
Primary outcome

To access the incidence and severity of adverse events (AEs), serious AEs and abnormalities on laboratory tests [Safety and Tolerability] of single ascending oral dose of XH-S004 in healthy adults.,To access the incidence and severity of adverse events (AEs), serious AEs and abnormalities on laboratory tests [Safety and Tolerability] of multiple ascending oral dose of XH-S004 in healthy adults.

Summary

This is a phase I, randomised, double-blind placebo-controlled, 3-part study to assess the
 safety, tolerability, pharmacokinetics and food effect of single and multiple oral doses of
 XH-S004 in healthy volunteers.

ICD-10 classifications
ObesityHealthy person accompanying sick personObesity, unspecifiedRoutine general health check-up of inhabitants of institutionsLifestyle-related condition
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06236841
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06236841 through Pure Global AI's free database. This Phase 1 trial is sponsored by S-Infinity Pharmaceuticals Co., Ltd and is currently Not yet recruiting. The study focuses on Healthy Adults. Target enrollment is 90 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.